Insider Profile · SEC Form 4 Activity · Trailing 90 Days
Ra Capital Nexus Fund Ii, L.p.
Over the trailing 90 days, Ra Capital Nexus Fund Ii, L.p. (Director at Hemab Therapeutics Holdings, Inc.) bought $104.8M of stock across 9 companies, per 33 SEC Form 4 transactions.
- Role
- Director
- Window
- Trailing 90 days · 33 transactions · CIK 1825376
- Net activity
- +$104.8M ($104.8M bought · $0 sold)
By Company (Trailing 90 Days)
| Symbol | Company | Txns | Bought | Sold | Net |
|---|---|---|---|---|---|
| FRNM | Freenome, Inc. | 7 | $52.6M | — | $52.6M |
| COAG | Hemab Therapeutics Holdings, Inc. | 15 | $52.2M | — | $52.2M |
| CLYM | Climb Bio, Inc. | 2 | — | — | $0 |
| SPRY | ARS Pharmaceuticals, Inc. | 1 | — | — | $0 |
| PEPG | PepGen Inc. | 1 | — | — | $0 |
| ACRV | Acrivon Therapeutics, Inc. | 2 | — | — | $0 |
| LENZ | LENZ Therapeutics, Inc. | 1 | — | — | $0 |
| JANX | Janux Therapeutics, Inc. | 2 | — | — | $0 |
| ABOS | Acumen Pharmaceuticals, Inc. | 2 | — | — | $0 |
Transactions (33)
| Date | Symbol | Type | Shares | Value | Description |
|---|---|---|---|---|---|
| 2026-07-20 | FRNM | Buy | 367.4K | $0 | Grant, award or other acquisition |
| 2026-07-20 | FRNM | Buy | 4.9M | $49.2M | Grant, award or other acquisition |
| 2026-07-20 | FRNM | Buy | 337.0K | $3.4M | Grant, award or other acquisition |
| 2026-07-20 | FRNM | Buy | 908.1K | $0 | Grant, award or other acquisition |
| 2026-07-20 | FRNM | Buy | 553.7K | $0 | Grant, award or other acquisition |
| 2026-07-20 | FRNM | Buy | 971.0K | $0 | Grant, award or other acquisition |
| 2026-07-20 | FRNM | Buy | 6.6M | $0 | Grant, award or other acquisition |
| 2026-06-29 | CLYM | Buy | 70.3K | $0 | Grant, award or other acquisition |
| 2026-06-24 | SPRY | Buy | 30.0K | $0 | Grant, award or other acquisition |
| 2026-06-18 | PEPG | Buy | 34.0K | $0 | Grant, award or other acquisition |
| 2026-06-17 | ACRV | Buy | 20.3K | $0 | Grant, award or other acquisition |
| 2026-06-15 | LENZ | Buy | 22.1K | $0 | Grant, award or other acquisition |
| 2026-06-11 | JANX | Buy | 15.5K | $0 | Grant, award or other acquisition |
| 2026-06-11 | JANX | Buy | 5.5K | $0 | Grant, award or other acquisition |
| 2026-06-05 | CLYM | Buy | 40.0K | $0 | Grant, award or other acquisition |
| 2026-06-03 | ABOS | Buy | 35.5K | $0 | Grant, award or other acquisition |
| 2026-06-03 | ABOS | Buy | 53.2K | $0 | Grant, award or other acquisition |
| 2026-05-18 | ACRV | Buy | 9.4K | $0 | Grant, award or other acquisition |
| 2026-05-06 | COAG | Buy | 14.6K | $347K | Open market or private purchase |
| 2026-05-06 | COAG | Buy | 53.4K | $1.3M | Open market or private purchase |
| 2026-05-05 | COAG | Buy | 10.3K | $257K | Open market or private purchase |
| 2026-05-05 | COAG | Buy | 87.1K | $2.1M | Open market or private purchase |
| 2026-05-04 | COAG | Sell | 10.1K | $0 | Conversion of derivative security |
| 2026-05-04 | COAG | Buy | 133.8K | $2.4M | Open market or private purchase |
| 2026-05-04 | COAG | Sell | 57.0K | $0 | Conversion of derivative security |
| 2026-05-04 | COAG | Buy | 221.2K | $0 | Conversion of derivative security |
| 2026-05-04 | COAG | Buy | 2.5M | $45.7M | Open market or private purchase |
| 2026-05-04 | COAG | Buy | 1.0M | $0 | Conversion of derivative security |
| 2026-05-04 | COAG | Buy | 3.6M | $0 | Conversion of derivative security |
| 2026-05-04 | COAG | Sell | 27.7K | $0 | Conversion of derivative security |
| 2026-05-04 | COAG | Sell | 18.1K | $0 | Conversion of derivative security |
| 2026-05-04 | COAG | Sell | 42.3K | $0 | Conversion of derivative security |
| 2026-05-04 | COAG | Sell | 64.7K | $0 | Conversion of derivative security |
Activity shown covers the trailing 90 days of SEC Form 4 filings. "Buy" and "sell" follow the SEC acquired/disposed codes and include compensation events (grants, option exercises, tax withholding) unless noted. Historical fact, not investment advice.
Follow Ra's next move
Real-time Form 4 alerts, insider track records, and cluster detection — matched to your watchlist.